• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Senate panel adds safety measures to FDA user fee act

Senate panel adds safety measures to FDA user fee act

April 25, 2012 By Brad Perriello

MassDevice.com news

A key U.S. Senate panel today approved a bill designed to tighten safety standards at the FDA’s medical device arm, but the committee’s markups to the measure failed to win support from consumer advocates.

The Senate’s Health, Education, Labor and Pensions Committee voted to approve the "Food & Drug Administration Safety and Innovation Act," which would beef up the FDA’s safety regulations, allowing the federal watchdog agency to conduct safety studies of devices after they’ve been approved and to grant conditional approvals contingent on further trials. The only "nay" in the voice vote was Sen. Bernie Sanders (I-Vt.).

The bill, known as the "Medical Device Safety Act" when it was introduced late last year by Sens. Chuck Grassley (R-Iowa), Herb Kohl (D-Wis.) and Richard Blumenthal (D-Conn.), would also strengthen the FDA’s 510(k) protocol, which allows device makers to show that their products are similar to already-cleared devices without requiring extensive clinical trials.

Hard on the heels of the panel’s vote today, the advocacy arm of Consumer Reports, Consumers Union, issued a statement saying the bill still does not go far enough to keep patients safe from the flaws in the 510(k) system.

"The FDA’s current fast track review process has allowed too many dangerous and defective devices onto the market," Lisa McGiffert, director of Consumers Union’s Safe Patient Project, said in prepared remarks. "To make matters worse, the FDA doesn’t have the tools it needs to react quickly when safety problems with medical devices arise. Unfortunately, this bill doesn’t fix some of the most serious flaws in our current system and leaves patients at risk."

The panel vetoed an amendment proposed by Sen. Jeff Merkley (D-Ore.) that would have given the FDA’s Center for Devices & Radiological Health "predicate nullification" authority – the ability to reject 510(k) applications based on recalled devices. Merkley formally withdrew the amendment ahead of the panel’s vote today, saying he hopes to negotiate it into the bill before it hits the full Senate floor for a vote.

"This seems like basic common sense," Merkley told colleagues today. "This is not a drastic revision. It says, ‘Look, you can still use a device as a predicate if you can show that that safety issue has been addressed.’"

Merkley’s amendment also would have beefed up the CDRH’s power to mandate post-market surveillance and set a deadline for implementing a universal identification program. The advocacy group said it backs Merkley’s proposals.

"Consumers Union has urged the committee to strengthen the bill by prohibiting the clearance of new medical devices based on recalled ones; improving the system for monitoring devices once they are cleared for sale; providing the FDA with greater authority to require post-market safety studies; and retaining current strong conflict of interest standards," according to the release.

The group said it opposes measures put forward by Sens. Rand Paul and Orrin Hatch that would "undermine current FDA standards on prescription drug and medical device recalls" and "prevent the FDA from up-classifying medical devices to require stricter safety testing."

Rand and Hatch also withdrew their amendments ahead of today’s vote. Like Merkley, they said they didn’t want to stand in the way of so-called "must-pass" legislation, which also contains the FDA’s budget and would double the user fees paid by medical device manufacturers. Congress has to get a bill to President Barack Obama by Oct. 1; the House Energy & Commerce Committee is slated to consider a companion bill tomorrow.

Filed Under: Food & Drug Administration (FDA), News Well Tagged With: MDUFMA, U.S. Senate

In case you missed it

  • Calyxo raises $32.7M for kidney stone treatment
  • Getinge anesthesia systems recall is Class I
  • RefleXion closes $125M debt facility
  • Senseonics announces equity grants to employees
  • New data backs Aerin’s RhinAer for treating chronic rhinitis
  • Enovis completes Insight Medical acquisition
  • Orchestra BioMed to go public, partner with Medtronic on cardiac neuromodulation therapy
  • Memic Innovative Surgery is now Momentis Surgical
  • Lyra Therapeutics appoints new chief medical officer
  • Masimo’s SafetyNet monitoring reduced length of COVID-19 hospital stays, study says
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy

RSS From Medical Design & Outsourcing

  • FDA can’t explain drop in device recalls, but experts point to COVID disruptions
    The FDA acknowledged interruptions with notifications from recalling firms during the pandemic, while regulatory experts point to fewer inspections and fewer procedures. FDA medical device product recalls dropped last year to their lowest level since 2013, according to a Medical Design & Outsourcing analysis of recall data from the regulatory agency. Medtech regulatory experts said the COVID-19… […]
  • DeviceTalks Boston 2022: Here’s what you missed on the show floor
    At DeviceTalks Boston 2022, there was a wealth of expertise to be had from exhibitors including Viant, ICS, PSN Labs, Propel and more. From stories of overcoming challenges during the COVID-19 pandemic to medical device materials pitfalls to avoid, MassDevice and MDO executive editor Chris Newmarker hit the DeviceTalks Boston show floor to discover insights. […]
  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS